Please login to the form below

Not currently logged in

UCB integrates two CROs into its clinical trial teams

Belgium pharma company agrees global research outsourcing deal with Parexel and PRA

UCB has signed partnership deals with two contract research organisations (CROs) that will see them operate as part of its global drug development team.

The agreements with Parexel and PRA will cover all the Brussels-based pharma company's new clinical trial programmes and they are also aimed at making UCB's studies more efficient and cost effective.

UCB's chief medical officer Iris Loew-Friedrich said: "We are pleased to announce these strategic partnerships as UCB aims to expand its global drug development activities, including in Asia.

“These partnerships represent long-term, win-win commitments to an outsourcing model focused on maximising the effectiveness of each participant's resources in clinical operations.”

The new arrangements will essentially see Parexel and PRA become integrated members of UCB's study teams, Loew-Friedrich added.

The company was light on the detail of the new agreements, saying the two CROs would “drive UCB's operational clinical development activities” and provide focused global operational clinical development activities.

Parexel said its service offering to UCB would include consulting expertise in regulatory affairs and commercialisation, while PRA said it has services for clinical studies across all phases and therapeutic areas with particular experience in CNS indications.

17th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch